ReviewiScience2026
Targeting the lethal weakness of SFTSV: Latest advances in antiviral strategies and immune prevention.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Serum interleukin-10 levels and mortality in severe fever with thrombocytopenia syndrome: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, severe fever with thrombocytopenia syndrome (SFTS), caused by the SFTS virus (SFTSV), has a fatality rate ranging from 12% to 50%, but there are currently no approved therapies to effectively treat the infection. Host cell receptors CCR2 and LRP1 have been identified as key entry points for viral invasion, and viral non-structural proteins evade the host innate immune response through multiple mechanisms. Several clinical studies have demonstrated that inflammatory markers (such as, IL-6, TNF-α, etc.), lipid metabolites, and ferritin are reliable prognostic indicators, aiding in early risk stratification. Favipiravir was associated with approximately a 10% reduction in mortality in clinical trials, while JAK inhibitors have shown efficacy in managing cytokine storms in critically ill patients. Recent drug repurposing studies have identified several FDA-approved compounds that show promise in combating SFTSV, potentially accelerating the development of therapeutic options. The comprehensive management of critically ill patients integrates multiple approaches, including antiviral therapy, immunomodulation, and organ function support, significantly improving clinical outcomes. Vaccine development has progressed across several platforms, including live attenuated and mRNA-based technologies. Several candidates have shown protective effects in animal studies, with improved formulations for high-risk elderly individuals. However, challenges remain in establishing protective immunity, ensuring long-term safety, and scaling up production for clinical use. This review summarizes recent progress in the transmission, pathogenesis, clinical features, immune response, prognosis, treatment, and vaccine development for SFTSV. It also identifies knowledge gaps and research limitations, proposing key areas for future focus to improve the management of this emerging infectious disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.